PE
ACAD icon

Point72 Europe’s Acadia Pharmaceuticals ACAD Stock Holding History

Point72 Europe’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$2.31M Sell
108,015
-26,940
-20% -$637K 0.11% 119
2025
Q2 		$2.91M Sell
134,955
-154,800
-53% -$2.88M 0.11% 122
2025
Q1 		$4.81M Buy
289,755
+116,600
+67% +$2.12M 0.33% 90
2024
Q4 		$3.18M Buy
+173,155
New +$2.79M 0.18% 96
2024
Q3 		– Sell
-50,600
Closed -$822K – 120
2024
Q2 		$822K Buy
+50,600
New +$817K 0.07% 125

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Point72 Europe's ACAD Position: Q3 2025 in Review

Point72 Europe reduced its Acadia Pharmaceuticals (ACAD) stake by 20% in Q3 2025, selling an estimated $637K and leaving 108,015 shares worth $2.31M. The position accounts for 0.11% of the portfolio, ranked #119.

Point72 Europe first reported a position in ACAD in Q2 2024 and has held it in 5 quarters since. The position peaked at $4.81M in Q1 2025. 334 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

  • Point72 Europe held 108,015 shares of Acadia Pharmaceuticals worth $2.31M as of Q3 2025.
  • Point72 Europe sold 26,940 Acadia Pharmaceuticals shares in Q3 2025, an estimated $637K.
  • Acadia Pharmaceuticals made up 0.11% of Point72 Europe's portfolio in Q3 2025, its #119 holding.
  • Point72 Europe first reported a position in Acadia Pharmaceuticals in Q2 2024 and has held it in 5 quarters since.
  • Point72 Europe's Acadia Pharmaceuticals position peaked at $4.81M in Q1 2025.
  • 334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.